Aptamer Group (LSE:APTA) has initiated a new radiopharmaceutical development programme through a collaboration with Radiopharmium Ltd, aimed at creating a proprietary pipeline of Optimer®-based radioconjugates targeting three high-value therapeutic indications.
The project builds on Aptamer’s existing partnership with a top-three global pharmaceutical company and is expected to expand the company’s radiotherapy portfolio to four development assets. Management is targeting the generation of in vivo data for the programme by the end of 2026.
According to internal research, Optimer® radioligands have demonstrated significantly improved stability compared with leading peptide-based alternatives when labelled with the therapeutic radioisotope Lutetium-177. If validated through further studies, the enhanced stability could extend product shelf life and simplify manufacturing and supply chain logistics for radiopharmaceutical therapies.
The initiative will be led by radiopharmaceutical specialist Dr Louis Allott, whose consultancy Radiopharmium will provide expertise in radiochemistry and access to preclinical testing models. The collaboration is intended to strengthen Aptamer’s efforts to differentiate its Optimer® platform and expand its presence in the rapidly growing market for targeted radiopharmaceutical therapies.
However, the company’s outlook remains constrained by weak financial performance, including a sharp decline in revenue, continued losses, and negative cash flow. Positive technical indicators — including an upward share price trend and supportive momentum — provide some offset, although valuation remains limited by the company’s lack of profitability and the absence of dividend distributions.
More about Aptamer Group plc
Aptamer Group plc is a UK-based life sciences company focused on developing synthetic binding molecules known as Optimer®. These next-generation binders are designed for use in research, diagnostics, and therapeutic applications. The company is increasingly positioning its Optimer® platform for emerging healthcare technologies, particularly in high-growth areas such as radiopharmaceuticals and targeted radioligand therapies.
Leave a Reply